Evaluation of the ability of the Clinical Treatment Score at 5 years (CTS5) compared to other risk stratification methods to predict the response to an extended endocrine therapy in breast cancer patients.
Andrea VillascoFrancesca AccomassoMarta D'AlonzoFrancesca AgnelliPiero SismondiNicoletta BigliaPublished in: Breast cancer (Tokyo, Japan) (2021)
Risk stratification according to CTS5 appeared to be predictive of the response to extended endocrine therapy in our population of real-life pre and postmenopausal patients.